Virus-Enhanced cocktail shows promise in stubborn myeloma
NCT ID NCT05514990
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people whose multiple myeloma has returned or stopped responding to at least three prior treatments. Researchers are testing whether adding a lab-modified virus (pelareorep) to a standard drug combination (bortezomib, dexamethasone, and pembrolizumab) can safely improve cancer control. The goal is to shrink tumors and delay progression, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer transplant study tests safer GVHD prevention
- New hope for hard-to-treat myeloma: three-drug combo enters phase 2 trial
- Stem cell transplant study seeks best way to prevent immune attack
- New immune cell therapy takes on Hard-to-Treat myeloma
- New combo tackles resistant myeloma in early trial
- New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients